involved Etanercept, which remained the commonest biological agent ever used. Etanercept was also the most frequent agent that was currently used by patients (24.7%). The number of patients who withdrew from treatment at different time points is shown in Table 3 . The three most commonly reported reasons for termination of treatment are lack of efficacy (46%), serious adverse effects (21%) and cost (11%). Other reasons for stopping treatment included marked improvement of disease activity (8%), end of research study (7%), patients' preference (3%) etc.
Major Adverse Events Reported

Neoplasia
There were 51 cases of malignant and pre-malignant conditions reported: lung cancer (N=5), rectum cancer (N=5), colon cancer (N=4), breast cancer (N=4), ovarian cancer (N=4), lymphoma (N=2), nasopharyngeal cancer (N=2), pulmonary MALT lymphoma (N=1), tongue cancer (N=1), caecum cancer (N=1), intraductal papillary mucinous neoplasm of pancreas (N=1), prostate cancer (N=1), stomach cancer (N=1), penile cancer (N=1), gall bladder cancer (N=1), cancer of urinary bladder (N=1), cancer of small intestine (N=1), kidney cancer (N=1), cancer of ampulla of vater (N=1), thyroid cancer (N=1), mandible cancer (N=1), adenocarcinoma (N=1), myeloma (N=1), cervical intra-epithelial neoplasia (CIN) (N=1), myelodysplastic syndrome (N=1), brain tumor (N=1), malignant melanoma (N=1), renal cell carcinoma (N=1), cervical cancer (N=1), cancer of nasal cavity (N=1), laryngeal cancer (N=1) and myeloproliferative neoplasms (N=1).
Infection Requiring Hospitalization
There were 172 episodes of infective complications requiring hospitalization. Over 55% of them (i.e. 95 cases) occurred during the first 12 months of biological therapy.
Tuberculosis
A total of 67 cases of TB were reported: 32 related to Infliximab, 12 related to Etanercept, 12 related to Adalimumab, 6 related to Golimumab, 3 related to Tocilizumab and 2 related to Tofacitinib. Half of the cases (i.e. 34 cases) occurred in the first year of treatment. Isoniazid chemoprophylaxis was given to 997 patients (22.3% of all courses of b/tsDMARDs) with latent TB as defined by either positive MT2 (≥10mm induration) or a positive IGRA test. 
Reasons for withdrawal
Lack 
